After further consumption of precious brain processing power, my take on the uplisting is that it is 99% tied to whether we get an EUA from any country. This news means revenues from 1M doses of leronlimab which should translate to a large increase in SP which would address any concerns NASDAQ has with the SP. In other words, I no longer consider uplisting as an event separate from EUA in the very near term.

Hopefully, this issue is put to rest soon after the meeting with the MHRA next week.